Inspired by the jets of water that squids use to propel themselves through the ocean, a team developed an ingestible capsule that releases a burst of drugs directly into the lining of the stomach or ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

MIT and Novo Nordisk researchers have developed a capsule that lets patients receive medications without injections. MIT News ...

Bagsværd, Denmark, 8 November 2024 - Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The ...

SINGAPORE - Media OutReach Newswire - 22 December 2023 - Novo Nordisk Pharma (Thailand) Ltd. has emerged triumphant by securing three prestigious accolades at the Asia Pacific Enterprise Awards (APEA) ...

LONDON, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 ...

Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The Danish pharma giant posted its third-quarter earnings report early ...

James Manning / PA Images / Getty Images After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...

LONDON, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the ...

COPENHAGEN (Reuters) - Novo Nordisk (NYSE:NVO) reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Novo Nordisk narrowed its full-year guidance after its blockbuster Wegovy weight-loss drug beat sales expectations. Soaring popularity for its obesity drug has seen demand far outstrip supply and ...